Plasma cells release membrane microparticles in a mouse model of multiple myeloma

Micron

Volumn 54-55, Issue , 2013, Pages 75-81

  Benameur, Tarek ^a,b   Chappard, Daniel ^a,c   Fioleau, Elodie ^a,c   Andriantsitohaina, Ramaroson ^a,b   Martinez, M Carmen ^a,b   Clere, Nicolas ^a,b   Marchand Libouban, Hélène ^a,c  

^a ISTIA Engineering School   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

CD138; Microenvironment; Microparticles; Multiple myeloma; Plasma B cells

Indexed keywords

B CELLS; CD138; MICRO-PARTICLES; MICROENVIRONMENTS; MULTIPLE MYELOMA;

BLOOD; BONE; CELL MEMBRANES; CYTOLOGY; MAMMALS;

PLASMAS;

MURINAE; MUS;

ANIMAL; ARTICLE; BONE MARROW CELL; CD138; CYTOLOGY; DISEASE MODEL; ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MEMBRANE MICROPARTICLE; MICROENVIRONMENT; MICROPARTICLES; MOUSE; MULTIPLE MYELOMA; PATHOLOGY; PLASMA; PLASMA B CELLS; PLASMA CELL; ULTRASTRUCTURE; WESTERN BLOTTING;

CD138; MICROENVIRONMENT; MICROPARTICLES; MULTIPLE MYELOMA; PLASMA B CELLS;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, ELECTRON; MULTIPLE MYELOMA; PLASMA; PLASMA CELLS;

EID: 84885924193     PISSN: 09684328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micron.2013.08.010     Document Type: Article

References (46)

1. Abe M., Hiura K., Ozaki S., Kido S., Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. Journal of Bone and Mineral Metabolism 2009, 27:16-23.
2. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., Kido S., Oshima T., Shibata H., Ozaki S., Inoue D., Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
3. Agouni A., Lagrue-Lak-Hal A.H., Ducluzeau P.H., Mostefai H.A., Draunet-Busson C., Leftheriotis G., Heymes C., Martinez M.C., Andriantsitohaina R. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. American Journal of Pathology 2008, 173:1210-1219.
4. Albarracin F., Fonseca R. Plasma cell leukemia. Blood Review 2011, 25:107-112.
5. Angelucci A., D'Ascenzo S., Festuccia C., Gravina G.L., Bologna M., Dolo V., Pavan A. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clinical and Experimental Metastasis 2000, 18:163-170.
6. Asosingh K., De Raeve H., Van Riet I., Van Camp B., Vanderkerken K. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003, 101:3136-3141.
7. Asosingh K., Radl J., Van Riet I., Van Camp B., Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematology Journal 2000, 1:351-356.
8. Auwerda J.J., Yuana Y., Osanto S., de Maat M.P., Sonneveld P., Bertina R.M., Leebeek F.W. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thrombosis and Haemostasis 2011, 105:14-20.
9. Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.L., Moreau P., Amiot M., Pellat-Deceunynck C. The phenotype of normal, reactive and malignant plasma cells. Identification of many and multiple myelomas and of new targets for myeloma therapy. Haematologica 2006, 91:1234-1240.
10. Castellana D., Toti F., Freyssinet J.M. Membrane microvesicles: macromessengers in cancer disease and progression. Thrombosis Research 2010, 125(Suppl. 2):S84L 88.
11. Choi S.J., Cruz J.C., Craig F., Chung H., Devlin R.D., Roodman G.D., Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96:671-675.
12. Croese J.W., Vas Nunes C.M., Radl J., van den Enden-Vieveen M.H., Brondijk R.J., Boersma W.J. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. British Journal of Cancer 1987, 56:555-560.
13. Croucher P.I., Shipman C.M., Van Camp B., Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003, 97:818-824.
14. Dashevsky O., Varon D., Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. International Journal of Cancer 2009, 124:1773-1777.
15. Dhodapkar M.V., Kelly T., Theus A., Athota A.B., Barlogie B., Sanderson R.D. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. British Journal of Haematology 1997, 99:368-371.
16. Elice F., Rodeghiero F. Hematologic malignancies and thrombosis. Thrombosis Research 2012, 129:360-366.
17. Ghosh A.K., Secreto C.R., Knox T.R., Ding W., Mukhopadhyay D., Kay N.E. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115:1755-1764.
18. Ginestra A., Miceli D., Dolo V., Romano F.M., Vittorelli M.L. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Research 1999, 19:3439-3445.
19. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., Grano M., Colucci S., Svaldi M., Rizzoli V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
20. Giuliani N., Morandi F., Tagliaferri S., Colla S., Bonomini S., Sammarelli G., Rizzoli V. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006, 107:841-842.
21. Kim C.W., Lee H.M., Lee T.H., Kang C., Kleinman H.K., Gho Y.S. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Research 2002, 62:6312-6317.
22. Kim H.K., Song K.S., Park Y.S., Kang Y.H., Lee Y.J., Lee K.R., Ryu K.W., Bae J.M., Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer 2003, 39:184-191.
23. Kristinsson S.Y. Thrombosis in multiple myeloma. Hematology/the Education Program of the American Society of Hematology 2010, 437-444.
24. Kukreja A., Hutchinson A., Dhodapkar K., Mazumder A., Vesole D., Angitapalli R., Jagannath S., Dhodapkar M.V. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. Journal of Experimental Medicine 2006, 203:1859-1865.
25. Laronne-Bar-On A., Zipori D., Haran-Ghera N. Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. Journal of Immunology 2008, 181:3714-3724.
26. Lee J.W., Chung H.Y., Ehrlich L.A., Jelinek D.F., Callander N.S., Roodman G.D., Choi S.J. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
27. Lemaire M., Deleu S., De Bruyne E., Van Valckenborgh E., Menu E., Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Advances in Cancer Research 2011, 110:19-42.
28. Libouban H., Moreau M.F., Basle M.F., Bataille R., Chappard D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 2003, 33:283-292.
29. Libouban H., Moreau M.F., Basle M.F., Bataille R., Chappard D. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse. Biochemical and Biophysical Research Communications 2004, 316:859-866.
30. Libouban H., Onno C., Pascaretti-Grizon F., Gallois Y., Moreau M.F., Baslé M.F., Chappard D. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells. Leukemia Research 2006, 30:1371-1375.
31. Martinez M.C., Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circulation Research 2011, 109:110-119.
32. Michigami T., Shimizu N., Williams P.J., Niewolna M., Dallas S.L., Mundy G.R., Yoneda T. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96:1953-1960.
33. Mitsiades C.S., McMillin D.W., Klippel S., Hideshima T., Chauhan D., Richardson P.G., Munshi N.C., Anderson K.C. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematology/Oncology Clinics of North America 2007, 21:1007-1034.
34. Mostefai H.A., Andriantsitohaina R., Martinez M.C. Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer. Physiological Research 2008, 57:311-320.
35. Muralidharan-Chari V., Clancy J.W., Sedgwick A., D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. Journal of Cell Science 2010, 123:1603-1611.
36. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., Tanaka Y., Shibata H., Hashimoto T., Ozaki S., Kido S., Inoue D., Matsumoto T. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106:3160-3165.
37. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., Choi Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:11581-11586.
38. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Seminars in Cancer Biology 2011, 21:139-146.
39. Roccaro A.M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., Shiraishi N., Ribatti D., Nico B., Vacca A., Dammacco F., Richardson P.G., Anderson K.C. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research 2006, 66:184-191.
40. Soleti R., Benameur T., Porro C., Panaro M.A., Andriantsitohaina R., Martinez M.C. Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis 2009, 30:580-588.
41. Standal T., Abildgaard N., Fagerli U.M., Stordal B., Hjertner O., Borset M., Sundan A. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109:3024-3030.
42. Tavoosidana G., Ronquist G., Darmanis S., Yan J., Carlsson L., Wu D., Conze T., Ek P., Semjonow A., Eltze E., Larsson A., Landegren U.D., Kamali-Moghaddam M. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:8809-8814.
43. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine 2003, 349:2483-2494.
44. Tual-Chalot S., Leonetti D., Andriantsitohaina R., Martinez M.C. Microvesicles: intercellular vectors of biological messages. Molecular Interventions 2011, 11:88-94.
45. Wijdenes J., Dore J.M., Clement C., Vermot-Desroches C. CD138. Journal of Biological Regulators and Homeostatic Agents 2002, 16:152-155.
46. Wijdenes J., Vooijs W.C., Clement C., Post J., Morard F., Vita N., Laurent P., Sun R.X., Klein B., Dore J.M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. British Journal of Haematology 1996, 94:318-323.